ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host the third and final webinar in its series of Key Opinion Leader (KOL) events on the emerging atopic dermatitis (AD) landscape and eblasakimab (ASLAN004) on Wednesday, June 22, 2022, at 10:00am ET.

For more information, please refer to the press release.